Jazz Pharmaceuticals Ltd. (JAZZ) was cut to a "neutral" rating by Goldman Sachs, with a price target of $196. In our last review of JAZZ back on May 14 we wrote that "Traders could go long JAZZ at current levels and on strength above $180. Risk to $169 for now. Our price targets going forward are $216, $244 and then $260." Traders would have been stopped out for a loss by late July.
More from Investing
These recently downgraded names are displaying both quantitative and technical deterioration.
LCID's market cap has been deflated, so is it now a bargain, or can it slip further?
The most powerful thing an investor can do is embrace the idea that they don't know what the future holds.
There high-growth dividend stocks will be here over the long haul.